Fmr LLC Invests $370,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Fmr LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,344 shares of the biotechnology company’s stock, valued at approximately $370,000. Fmr LLC owned approximately 0.05% of Capricor Therapeutics at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Main Street Financial Solutions LLC boosted its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics during the 2nd quarter valued at about $147,000. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics in the third quarter valued at about $161,000. Finally, Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $12.90 on Friday. The business’s fifty day moving average price is $18.12 and its two-hundred day moving average price is $10.20. The firm has a market capitalization of $586.56 million, a price-to-earnings ratio of -12.17 and a beta of 3.98. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40.

Analysts Set New Price Targets

Several analysts have recently weighed in on CAPR shares. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, November 14th. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target for the company. Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group raised their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Cantor Fitzgerald lifted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.